Spliceor Ltd is an early-stage research and development biotechnology company spun out from the Department of Medicine, University of Cambridge, U.K.
Spliceor is developing gene therapies for aggressive cancers for which current treatments are ineffective.
Our mission is to provide tumour-selective and easily tolerated gene therapies to cancer patients. The underlying technology platform also has many applications for potential treatment of other diseases beyond cancer, in our future therapeutic pipeline development.
During normal gene expression introns are removed from pre-mRNA by the process of splicing. Ordinarily cis-splicing occurs across a single pre-mRNA molecule, allowing neighbouring exons to be joined together.
Trans-splicing is a special case, where exons from two or more different pre-mRNA molecules are brought together, forming chimeric mRNA, which may lead to the expression of proteins with novel functions.
At Spliceor, we leverage RNA trans-splicing to generate therapeutic effector mRNA in specific cell types, making use of machine learning with public and proprietary datasets to optimise design.
We are developing our technology to treat aggressive cancers and other diseases with significant unmet clinical need.
Spin-out from the University of Cambridge
Spliceor is backed by investors with expertise in technology and life sciences.
